Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 9/20 | 0.58 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1624451 | 1.00 | SMO (0.58) | SMOBRD4DGAT2HDAC1HDAC8 | |
| SCHEMBL1624522 | 0.97 | SMO (0.56) | SMOBRD4DGAT2HDAC1HDAC8 | |
| SCHEMBL1624660 | 0.94 | SMO (0.58) | SMOBRD4DGAT2HDAC1HDAC8 | |
| SCHEMBL1622920 | 0.94 | SMO (0.58) | SMOBRD4DGAT2HDAC1HDAC8 | |
| SCHEMBL1624927 | 0.94 | SMO (0.58) | SMOBRD4DGAT2HDAC1HDAC8 | |
| SCHEMBL1624291 | 0.94 | SMO (0.57) | SMOBRD4DGAT2HDAC1HDAC8 | |
| SCHEMBL1623715 | 0.94 | SMO (0.57) | SMOBRD4DGAT2HDAC1HDAC8 | |
| SCHEMBL1624800 | 0.94 | SMO (0.57) | SMOBRD4DGAT2HDAC1HDAC8 | |
| SCHEMBL13033856 | 0.92 | SMO (0.60) | SMOHDAC1HDAC8HDAC6SMN1; SMN2 | |
| SCHEMBL1624939 | 0.91 | SMO (0.49) | SMOBRD4DGAT2HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592463-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2013-11-26 | — | — | US | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | SMO 3/4885BRD4 458/4885DGAT2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.